Literature DB >> 6292875

IgM to varicella-zoster virus: demonstration in patients with and without clinical zoster.

A A Gershon, S P Steinberg, W Borkowsky, D Lennette, E Lennette.   

Abstract

Antibody to varicella-zoster (VZ) virus of the IgM type was detected in sera from 50% of persons with clinical zoster, 67% of asymptomatic varicella immunes with a recent intimate exposure to VZ virus and 22 to 40% of varicella immunes with no symptoms of zoster or known exposure to the virus. No VZ IgM was found in newborn sera or in sera from persons susceptible to varicella, demonstrating specificity of the VA IgM assay. Since development of specific IgM is associated with acute infection, these data suggest that reinfection with VA virus occurs and also that antigenic stimulation due to exposure to endogenous VZ virus may occur. We hypothesize that during reactivation of VZ virus, persons with intact VZ cell-mediated immunity (CMI) remain asymptomatic but that those with depressed VZ CMI may develop clinical zoster. These data suggest that there is an unstable relationship between VZ virus and the human host.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292875     DOI: 10.1097/00006454-198205000-00007

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  9 in total

1.  Antibody-capture enzyme-linked immunosorbent assays that use enzyme-labelled antigen for detection of virus-specific immunoglobulin M, A and G in patients with varicella or herpes zoster.

Authors:  A M van Loon; J T van der Logt; F W Heessen; M C Heeren; J Zoll
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

2.  Sensitivity of different assay systems for immunoglobulin M responses to varicella-zoster virus in reactivated infections (zoster).

Authors:  N J Schmidt; A M Arvin
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

3.  Detection of specific IgM in varicella and herpes zoster by antibody-capture radioimmunoassay.

Authors:  H O Kangro; A Ward; S Argent; R B Heath; J E Cradock-Watson; M K Ridehalgh
Journal:  Epidemiol Infect       Date:  1988-08       Impact factor: 2.451

4.  Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Authors:  Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

5.  Antibody class capture assays for varicella-zoster virus.

Authors:  B Forghani; C K Myoraku; K W Dupuis; N J Schmidt
Journal:  J Clin Microbiol       Date:  1984-05       Impact factor: 5.948

6.  Herpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination.

Authors:  James G Donahue; Burney A Kieke; Paul M Gargiullo; Aisha O Jumaan; Nicholas R Berger; Jeremy S McCauley; Edward A Belongia
Journal:  Am J Public Health       Date:  2010-01-14       Impact factor: 9.308

7.  Immunity to varicella zoster virus in children with leukaemia.

Authors:  P M Ndumbe; K Wheeler; J M Chessells; R J Levinsky
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

Review 8.  Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.

Authors:  Benson Ogunjimi; Pierre Van Damme; Philippe Beutels
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

9.  The positive duration of varicella zoster immunoglobulin M antibody test in herpes zoster.

Authors:  Seong-Won Min; Yung Suk Kim; Francis Sahngun Nahm; Da Hye Yoo; Eunjoo Choi; Pyung-Bok Lee; Hyunjung Choo; Zee-Yong Park; Catherine Seonghee Yang
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.